Targets › SOD1
7 programs from 7 companies in 10 trials: 6 Phase 1, 2 Phase 2, 1 Phase 4, 1 Phase 3; Neurology, Other, Oncology; next expected readout Jan 2027.
Destroys radicals which are normally produced within the cells and which are toxic to biological systems. Catalyzes the oxidation of hydrogen sulfide (H2S) to sulfate, playing an important role in detoxifying H2S and limiting the accumulation of reactive sulfur species (RSS) such as persulfides and polysulfides. (UniProt, P00441)
Open in Phaseline: the race on SOD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biogen | Tofersen SOD1 mRNA antisense inhibitor | SOD1 | Phase 4 | Amyotrophic Lateral Sclerosis; Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation; ALS (Amyotrophic Lateral Sclerosis) | May 2027 |
| West China Hospital | superoxide dismutase skin spray antioxidant enzyme that catalyzes the dismutation of superoxide radicals | SOD1, SOD2, SOD3 | Phase 2 | Radiation-induced Dermatitis | Jan 2027 |
| Insmed Gene Therapy | INS1202 Gene therapy targeting SOD1 mutations | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis | Mar 2030 |
| UniQure Biopharma | AMT-162 Self-complementary AAV serotype rh10 vector delivering miRNA targeting SOD1 | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis | Jun 2031 |
| Regeneron Pharmaceuticals | ALN-SOD SOD1 mRNA inhibitor (RNAi therapeutic) | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis (ALS) | Mar 2032 |
| Ractigen Therapeutics. | RAG-17 SOD1 mRNA targeting siRNA | SOD1 | Phase 1 | Amyotrophic Lateral Sclerosis | – |
| Beijing Tiantan Hospital | Y-4 tablet Fixed-dose combination of pregabalin (GABA analog/anticonvulsant) and riluzole (glutamate | GABRA1, SOD1 | Phase 1 | Healthy Male and Female Subjects | – |
Amyotrophic Lateral Sclerosis (4) Healthy Male and Female Subjects (2) Radiation-induced Dermatitis (1) Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation (1) ALS (Amyotrophic Lateral Sclerosis) (1) Amyotrophic Lateral Sclerosis (ALS) (1)
small molecule (4), other (2), protein or peptide (1)
Beijing Tiantan Hospital (1) West China Hospital (1) UniQure Biopharma (1) Biogen (1) Regeneron Pharmaceuticals (1) Insmed Gene Therapy (1) Ractigen Therapeutics. (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.